Schytte T, Knap MM, Kristiansen C, Appelt AL, Khalil A, Peucelle C, Lutz CM, Møller DS, Sande EPS, Sundby F, Persson G, Schmidt H, Land LH, Rogg L, Pøhl M, Lund MD, Nielsen M, Levin N, Hansen O, Thing RS, Borissova S, Halvorsen T, Nielsen TB, Hansen TS, Haakensen VD et al. (2025)
Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial
J Clin Oncol, JCO2401386 (in press)
DOI 10.1200/JCO-24-01386, PubMed 40249893

Dechow A, Timonen S, Ianevski A, Jiang Q, Wahnschaffe L, Peng Y, Jungherz D, Becker K, Neubauer HA, Schönefeldt S, de Araujo E, Gunning P, Fleck R, Schrader A, Hallek M, Pflug N, Moriggl R, Aittokallio T, Mustjoki S, Braun T, Herling M (2025)
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia
Leukemia (in press)
DOI 10.1038/s41375-025-02577-8, PubMed 40234614

Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT, Grønberg BH (2025)
Corrigendum: Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients - a nationwide and longitudinal study
Front Oncol, 15, 1595028
DOI 10.3389/fonc.2025.1595028, PubMed 40206591